New York, NY (PRWEB) December 27, 2013
Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by Medical News Today that discusses a new brain cancer vaccine called HSPPC-96, which is personally molded to each patient’s genetic makeup.
According to the December 19th article published by Medical News Today titled “Promising results for personalized brain tumor vaccine,” patients with Gliobastoma Multiforme (GBM) brain tumors, when going through standard treatment, have a median survival rate of three to nine months. The new vaccine is developed specifically to each patient using his or her own respected tumor tissue. Investigators say the vaccine works by “prompting an immune system response unique to each patient, which sets out to kill any remaining tumor cells following surgery.”
The article states that 90 percent of patients lived after six months of treatment with this vaccine, while 30 percent lived after one year. However, more research is needed before receiving approval to use this treatment for GBM’s.
Researchers have to determine if the vaccine is safer and more effective when used alongside Avastin, a drug that is standard for therapy against GBM’s and known to reduce tumor size.
Michael Klipper, Chairman of Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, believes that with more research, this vaccine could be very helpful. “Evidently, additional extensive research has to be done with this vaccine. If results are consistently positive, this vaccine could be a game changer in the treatment of these deadly and aggressive brain tumors,” he says. “Regardless, the fact that this type of treatment is even a possibility, serves as a glimmer of hope for everyone in the brain cancer community.”
VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization’s research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, Johns Hopkins, Memorial Sloan-Kettering and Yale, to name a few.
VABC's mission is to find a cure for brain cancer by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers afflicted with this devastating disease.
For press inquiries, please contact: 5W Public Relations.
Read the full story at http://www.prweb.com/releases/2013/12/prweb11445639.htm.
Copyright©2012 Vocus, Inc.
All rights reserved